Navigation Links
Avaxia Biologic's Barbara Fox Named one of Mass High Tech's Women to Watch in 2012
Date:3/1/2012

LEXINGTON, Mass., March 1, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that Dr. Barbara Fox, its founder and CEO, has been was named one of Mass High Tech's Women to Watch in 2012.  Mass High Tech's 9th annual Women to Watch awards recognize women in the fields of technology and life sciences, "who are go-getters, hardworking, inspirational and motivational to their peers."

Dr. David Poorvin, member of the Board of Directors of Avaxia, commented, "We are truly proud of this recognition of Dr. Fox's achievements.  She has been instrumental in building Avaxia Biologics from a creative idea into a developmental biotech company that will be testing its first drug candidate later this year. She is not only an innovative scientist, but also a motivational executive who leads by example.  We are confident that she will continue to have a significant impact on drug development and the biotech communities in Massachusetts for years to come."

Prior to founding Avaxia Biologics, Dr. Fox was the founder, President and Chief Scientific Officer of Recovery Pharmaceuticals, a company developing and marketing medications for the treatment of addiction. Prior to founding Recovery Pharmaceuticals in 1998, she was Vice President, Immunology at ImmuLogic Pharmaceutical Corp. She joined ImmuLogic in 1993, having served on the faculty of the University Maryland School of Medicine, Baltimore, as Associate Professor of Medicine with tenure in the Division of Rheumatology and Clinical Immunology, Dept. of Medicine. Dr. Fox received her BA in Chemistry from Bryn Mawr College and her Ph.D. in Chemistry from MIT. Dr. Fox trained as a post-doc in cellular immunology at the NIH.

Mass High Tech will honor Dr. Fox and 19 other awardees at an awards breakfast on Friday, May 11, 2012 at the Fairmont Copley Plaza.

About Avaxia Biologics, Inc.: Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
4. Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Companys Synthetic Biologics Strategic Focus
5. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
6. Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development
7. BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
8. Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
9. ResearchMoz: Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
10. US Biologics Market
11. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... 30, 2017 In vitro diagnostics market firm ... May, at least ten diagnostic companies have successfully completed ... offerings and a loan facility.  The size of these ... million.  Kalorama Information provides a monthly IVD Market ... Knowledge Center. ...
(Date:6/30/2017)... POINT, N.C. , June 29, 2017  Axium Pharmaceuticals Inc. ... for developing improved novel formulations and alternative dosage forms of ... ... delivery is based on our waterless self-nano emulsifying formula, which ... contact with saliva. We believe the spray will provide fast ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... ... 2307 Bellmore Avenue, Bellmore, New York, (516) 784-5858. The office opened earlier this ... physician assistants Lori Friedman and Fruma Leah Wiederman. , Advanced Dermatology, P.C. ...
(Date:7/24/2017)... ... , ... The Center for Addiction Recovery Training (CART), the ... second Multiple Pathways of Recovery Conference on October 23-26, 2017. This year, the ... foundational principle – a belief in multiple pathways of recovery, aims to bring ...
(Date:7/23/2017)... ... July 23, 2017 , ... Better education ... say researchers presenting their work today at the American Orthopaedic Society for ... is the first one to prospectively document the association between sports specialization and ...
(Date:7/23/2017)... ... 2017 , ... “Squiggy’s Outdoor Adventure”: a turtle’s backyard adventure that teaches the ... author, Paula Christian, a wife and mother to three amazing, and supportive, children. ... lives on God. She loves to tell stories to her children, play board ...
(Date:7/21/2017)... ... July 21, 2017 , ... "As a doctor of lung ... pleural catheters available on the market," said an inventor from Center Valley, Pa. "My ... for the patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer ...
Breaking Medicine News(10 mins):